MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief medical officer Nadya Lisovoder speaks to Proactive's Thomas Warner after announcing the completion of an in-vitro pre-clinical mechanism of action (MoA) study for the European based bio-pharma company's CimetrA platform.
Lisovoder says that the fact MGC "totally understands" CimetrA represents a "very important step" in the development process.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
